Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]SHR4640 in Healthy Volunteers
NCT04260373Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruzinurad in gout and hyperuricemia, sponsored by Hengrui. Primary endpoints: Quantitive analysis of whole radioactivity of excrement up to 10 days, Concentrations of SHR4640 in plasma up to 10 days and 1 more. Started Mar 2020; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04260373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260373.